Kidney Cancer Clinical Trial
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Summary
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically confirmed renal cell cancer with a component of clear cell subtype, with metastasis
Evidence of measurable disease
Must have failed one prior systemic first-line regimen for metastatic renal cell cancer
Exclusion Criteria:
Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy
Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.